tbuckley/cabot-search huggingface dataset:
Imaging findings related to adjuvant dendritic cell (DC) vaccination in patients with relapsed high-grade glioma
Authors: Frank Van Calenbergh, Stefaan Van Gool, Jan Goffin, Guy Wilms, Philippe Demaerel, Koen Van Laere, Raphael Sciot, Stefan Rutkowski, Johannes E. A Wolff, Steven De Vleeschouwer
Journal: Neuro-Oncology (2006)
The Non-Steroidal Fxr Agonist Gs-9674 Reduces Liver Fibrosis and Ameliorates Portal Hypertension in a Rat Nash Model
Authors: P. Schwabl, E. Hambruch, P. Supper, M. Burnet, M. Peck-Radosavljevic, T. Reiberger, C. Kremoser, M. Trauner
Journal: Journal of Hepatology (2016)
Biliary Tract Cancer with or without Primary Sclerosing Cholangitis is Associated with a Raised Enhanced Liver Fibrosis Test Result Compared with PSC Alone
Authors: F. Saffioti, D. Roccarina, M. Vesterhus, J.R. Hov, W. Rosenberg, M. Pinzani, T.H. Karlsen, S.P. Pereira, K.M. Boberg, D. Thorburn
Journal: Journal of Hepatology (2016)
Exome Sequencing Derived Alloreactivity Potential May Predict Gvhd in Allogeneic Stem Cell Transplantation
Authors: Max Jameson-Lee, Allison F Scalora, Vishal Koparde, David Jared Kobulnicky, Badar Abdur Razzaq, Andrea Ferreira-Gonzalez, Myrna G. Serrano, Catherine H. Roberts, Gregory Buck, Michael C. Neale, Amir A. Toor
Journal: Blood (2015)
Exogenous Administration of SERPINB3 Inhibits Cell Reprogramming
Authors: E. Torchip, S. Quarta, S. Giulitti, C. Turato, A. Biasiolo, C. Luni, M. Ruvoletto, G. Villano, G.G. Giobbe, P. Pontisso, N. Elvassore
Journal: Journal of Hepatology (2016)
Accuracy of the Radiological Diagnosis of Hepatocellular Carcinoma outside the Periodic Surveillance with Ultrasound
Authors: M. Iavarone, C. Della Corte, M. Vigano, N.O.S. Piazza, L. Miglioresi, A. Aghemo, A. Sangiovanni, M.G. Rumi, M. Colombo
Journal: Journal of Hepatology (2016)
Light to Moderate Alcohol Use is not Associated with Long-Term Progression of Liver Fibrosis in Hiv Hcv Coinfected Women
Authors: E.M. Kelly, J. Dodge, P. Bacchetti, M. Sarkar, A. French, P. Tien, M. Glesby, E. Golub, M. Augenbraun, M. Plankey, M. Peters
Journal: Journal of Hepatology (2016)
Primary Prophylaxis For Variceal Bleeding Should be done for Patients with Hepatocellular Carcinoma
Authors: J.H. Kim, D.H. Sinn, J.H. Lee, W. Kang, G.-Y. Gwak, Y.-H. Paik, M.S. Choi, J.H. Lee, K.C. Koh, S.W. Paik
Journal: Journal of Hepatology (2016)
Hepatocellular Carcinoma in Non-Alchoolic Steatohepatitis – Histopathological Aspects
Authors: P.B. de Campos, C.P. Oliveira, L. Kikuchi, J.T. Stefano, A.L. Chagas, P. Herman, L.C. D’albuquerque, M.R. Alvares da Silva, F.J. Carrilho, V.A. F. Alves
Journal: Journal of Hepatology (2016)
Real-World Data on the use of Ribavirin with Ombitasvir/Paritaprevir/R with or without Dasabuvir in HCV Genotype 1 or 4-Infected Patients from the German Hepatitis C Registry
Authors: T.M. Welzel, P. Buggisch, T. Berg, K. Stein, J. Hettinger, H. Kleine
Journal: Journal of Hepatology (2016)
Lack of Improvement of Liver Stiffness during Sofosbuvir-Treatment in Decompensated Cirrhotic Patients Listed for Liver Transplant Seems to be Associated with more Severe Histological Damage in the Native Liver
Authors: F. Invernizzi, F. Malinverno, M. Maggioni, A. Sciarra, A. Aghemo, D. Dondossola, G. Rossi, M. Colombo, M.F. Donato
Journal: Journal of Hepatology (2016)
Outcome of Patients (pts) with Acute Myeloid Leukemia (AML) Evolving From Myelodysplastic Syndromes (MDS) Post Hypomethyling Agents (HMA) Failure
Authors: Hady Ghanem, Hagop M. Kantarjian, Guillermo Garcia Manero, Farhad Ravandi, Jorge E. Cortes, Koichi Takahashi, Susan M. O'Brien, Sherry A. Pierce, Tapan M. Kadia, Elias J. Jabbour
Journal: Blood (2012)
Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma
Authors: Jean-Francois Rossi, Robert F. Manges, Heather J. Sutherland, Sundar Jagannath, Peter Voorhees, Pieter Sonneveld, Michel Delforge, Brigitte Pegourie, Adrian Alegre, Javier de la Rubia, David La Police, Rajesh Bandekar, Hong Xie, Robert Z. Orlowski
Journal: Blood (2008)
Effects of Plasmapheresis on Pruritus in Patients with PBC: Prospective Analysis of 121 Procedures Performed in a Single Center
Authors: M. Krawczyk, R. Liebe, M. Wasilewicz, E. Wunsch, J. Raszeja-Wyszomirska, P. Milkiewicz
Journal: Journal of Hepatology (2016)
C/EBP Suppression by Interruption of CUGBP1 Resulting from a Complex Rearrangement of MLL.
Authors: William T. Choi, Matthew R. Folsom, Mohammed F. Azim, Claus Meyer, Eric Kowarz, Rolf Marschalek, Nicolai A. Timchenko, Rizwan A. Naeem, Dean A. Lee
Journal: Blood (2006)
Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells are Abundant in HCV-Seronegative Individuals and can Show Cross-Reactivity to Common Pathogens
Authors: S. Zhang, S.P. Venkata, V. Schlaphoff, A. Markova, S.O. Sekyere, M.P. Manns, H. Wedemeyer, M. Cornberg
Journal: Journal of Hepatology (2016)
Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity
Authors: Iago Pinal-Fernandez, Maria Casal-Dominguez, John A Carrino, Arash H Lahouti, Pari Basharat, Jemima Albayda, Julie J Paik, Shivani Ahlawat, Sonye K Danoff, Thomas E Lloyd, Andrew L Mammen, Lisa Christopher-Stine
Journal: Annals of the Rheumatic Diseases (2016)

Objectives The aims of this study were to define the pattern of muscle involvement in patients with immune-mediated necrotising myopathy (IMNM) relative to those with other inflammatory myopathies and to compare patients with IMNM with different autoantibodies. Methods All Johns Hopkins Myositis Longitudinal Cohort subjects with a thigh MRI (tMRI) who fulfilled criteria for IMNM, dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) or clinically amyopathic DM (CADM) were included in the study. Muscles were assessed for intramuscular and fascial oedema, atrophy and fatty replacement. Disease subgroups were compared using univariate and multivariate analyses. Patients with IMNM with anti-signal recognition particle (SRP) autoantibodies were compared with those with IMNM with anti-HMG-CoA reductase (HMGCR) autoantibodies. Results The study included 666 subjects (101 IMNM, 176 PM, 219 DM, 17 CADM and 153 IBM). Compared with DM or PM, IMNM was characterised by a higher proportion of thigh muscles with oedema, atrophy and fatty replacement (p&lt;0.01). Patients with IMNM with anti-SRP had more atrophy (19%, p=0.003) and fatty replacement (18%, p=0.04) than those with anti-HMGCR. In IMNM, muscle abnormalities were especially common in the lateral rotator and gluteal groups. Fascial involvement was most widespread in DM. Fatty replacement of muscle tissue began early during the course of disease in IMNM and the other groups. An optimal combination of tMRI features had only a 55% positive predictive value for diagnosing IMNM. Conclusions Compared with patients with DM or PM, IMNM is characterised by more widespread muscle involvement. Anti-SRP-positive patients have more severe muscle involvement than anti-HMGCR-positive patients.
Phase II trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and intensity moduled radiation therapy (IMRT) for locally advanced head and neck cancer
Authors: J. Kao, L. Policarpio, M. Teng, R. Burri, E. Genden, S. Packer
Journal: Journal of Clinical Oncology (2009)

6014 Background: This phase II study was conducted to evaluate the tolerability and efficacy of incorporating cetuximab and simultaneous integrated boost intensity modulated radiation (SIB-IMRT) into a well-described 5-fluorouracil (5-FU) and hydroxyurea (HU)-based chemoradiation regimen. Endpoints included overall survival (OS), locoregional (LRC) and (DC), quality of life and toxicity. Methods: Patients with stage IVa-IVb or high-risk stage III squamous cell carcinomas were enrolled on a phase II trial. Prior organ-conserving surgical therapy or induction chemotherapy was allowed off protocol. SIB-IMRT was prescribed to low (43.2 to 48 Gy) and intermediate (54 to 63 Gy) risk volumes. A separate IMRT conedown plan was targeted to gross disease (72 Gy). The median radiation dose was 72 Gy (range 60 to 72 Gy) administered in 1.5 Gy fractions BID on weeks 1, 3, 5, 7 ± 9. Concurrent systemic therapy consisted of 5-FU (600 mg/m2), HU (500 mg BID) and cetuximab (250 mg/m2). Results: From January 2007 to April 2008, 33 subjects enrolled. Characteristics included 24 males; median age 59; ECOG performance status was 0 in 12. Disease was stage IVa-b disease in 31 (94%), T3–4 in 16 (48%), N2–3 in 23 (70%), and oropharynx primary in 15 (45%). Median follow-up in surviving patients is 15 months (range 6 to 22 months). The 1 year LRC, DC and OS is 91%, 82%, and 92%, respectively. Grade 3 toxicity consisted of mucositis (33%), radiation dermatitis (15%), anemia (15%), and leukopenia (15%), and neutropenia (9%). There were no grade 4–5 events. The majority of patients (64%) were able to tolerate treatment without a feeding tube. Median patient reported University of Washington QOL-R scores before, immediately after, 3 months and 8 months after chemoradiation were 85.5 (±14), 65 (±13), 76.5 (±15), and 84.5 (±9), respectively. Conclusions: Concurrent 5-FU, HU, cetuximab, and SIB-IMRT is a promising and reasonably well tolerated approach to incorporating molecularly targeted therapy in the curative therapy of locally advanced head and neck cancer. [Table: see text]
HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy
Authors: Elena Knops, Niels Schübel, Eva Heger, Maria Neumann-Fraune, Rolf Kaiser, Stephanie Inden, Prabhav Kalaghatgi, Saleta Sierra
Journal: Clinical Gastroenterology and Hepatology (2016)
Ischemia/Reperfusion Injury in the Aged Liver: The Importance of the Sinusoidal Endothelium in Developing Therapeutic Strategies for the Elderly
Authors: D. Hide, M. Ortega-Ribera, A. Warren, D. Le Couteur, J. Bosch, V. Cogger, J. Gracia-Sancho
Journal: Journal of Hepatology (2016)
Prevention of Viral Spread, Viremia Reduction and HBsAg Clearance in Hepatitis B and D Coinfected Humanized Mice by a Human Neutralizing Monoclonal Antibody
Authors: D. Corti, T. Volz, K. Giersch, G. Agatic, E. Cameroni, J. Kah, L. Allweiss, A. Schulze, A.W. Lohse, J. Petersen, S. Urban, M. Lütgehetmann, A. Lanzavecchia, M. Dandri
Journal: Journal of Hepatology (2016)
Homeostasis Model Assessment-IR and Leptin as a Predictors of Liver Fibrosis among Patients with Chronic Hepatitis B Virus Infection
Authors: N. Mousa, A. Abdel-Razik, N. El-Wakeel, S. Elbaz, N. Effat, W. Elkashef, W. Eldars
Journal: Journal of Hepatology (2016)
Exploiting a host-commensal interaction to promote intestinal barrier function and enteric pathogen tolerance
Authors: Virginia A. Pedicord, Ainsley A. K. Lockhart, Kavita J. Rangan, Jeffrey W. Craig, Jakob Loschko, Aneta Rogoz, Howard C. Hang, Daniel Mucida
Journal: Science Immunology (2016)

A secreted bacterial protein protects worms and mice from Salmonella pathogenesis.
David Oliver: Reducing delays in hospitals
Authors: David Oliver
Journal: BMJ (2016)

I’ve written before about rising demand for acute care in the United Kingdom, insufficient capacity in community services, delayed transfers of care, and the comparatively low number and high occupancy of hospital beds.1 2 3 4 But hospitals shouldn’t default to blaming other services. Some of the major variation in bed occupancy among hospitals might be explained by what happens there—our internal processes and delays.5 6 7

> Hospitals shouldn’t default to blaming other services

Here are some suggestions on how we might tackle the problems, but I’m hardly alone in making …
The clinical outcome of a pilot study in primary renal transplant patients investigating the feasibility of using a low tacrolimus low-stop steroid immunosuppressive regimen in combination with daclizumab and mycophenolate mofetil to reduce cardiovascular and renal immunosuppressive side-effects
Authors: D Abramowicz, Yves Vanrenterghem, JP Squifflet, Drj Kuypers, M Mourad, M Meurisse, J Daems
Journal: Journal of the American Society of Nephrology (2002)
Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.
Authors: Paul Richardson, Rudolf Schlag, Nuriet K Khuageva, Meletios A. Dimopoulos, Ofer Shpilberg, Martin H Kropff, Michel Delforge, Maria Teresa Petrucci, Victor A Rossiev, Jian Hou, Tadeusz Robak, Maria-Victoria Mateos, Kenneth C. Anderson, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesus F. San Miguel
Journal: Blood (2008)
Mortality among Patients with Chronic Hepatitis C and Cirrhosis in Denmark – A Nationwide Danhep Cohort Study
Authors: S. Hallager, P.B. Christensen, A.M.R. Clausen, A.L. Laursen, A. Møller, P. Schlichting, L.G. Madsen, J. Gerstoft, S. Lunding, K.E. Grønbæk, H.B. Krarup, N.M. Weis
Journal: Journal of Hepatology (2016)
Beyond disjoint brain networks: Overlapping networks for cognition and emotion
Authors: Luiz Pessoa
Journal: Behavioral and Brain Sciences (2016)

Abstract It is taken for granted that the brain is composed of a set of networks. But what is a brain network? How should we characterize them? Adding to Anderson's (2014) persuasive anti-modular framework, I propose that (1) networks do not have a single, unique function; (2) networks are highly overlapping and not disjoint; and (3) tasks reconfigure networks found at rest.
Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate use Program
Authors: T. Welzel, J. Petersen, K. Herzer, P. Ferenci, M. Gschwantler, M. Cornberg, P. Ingiliz, T. Berg, U. Spengler, O. Weiland, M. van der Valk, H. Klinker, J. Rockstroh, M. Peck-Radosavljevic, Y. Zhao, M.J. Jimenez-Exposito, S. Zeuzem
Journal: Journal of Hepatology (2016)
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, with or without Ribavirin, in Adults Treated with the Regimen Approved in Australia, Canada, New Zealand, and Switzerland
Authors: E. Gane, S.I. Strasser, J. Feld, J.-F. Dufour, D. Crawford, S. Roberts, T. Satyanand, M. Kapoor, L. Larsen, T. Podsadecki
Journal: Journal of Hepatology (2016)
High Sustained Virologic Response Rates in Patients Infected with Genotype 2 with Baseline NS5A Polymorphisms Treated with Daclatasvir-Based Regimens
Authors: N. Zhou, Z. Han, S.H. Neumann, B. DeGray, J. Ueland, V. Vellucci, D. Hernandez, F. McPhee
Journal: Journal of Hepatology (2016)
Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order
Authors: Susann Szmania, Natalia Lapteva, Tarun K. Garg, Joshuah D Lingo, Amy D Greenway, Amberly Bost, Katie Stone, Junaid Khan, Emily Woods, Bijay Nair, Dario Campana, Joshua Epstein, Malcolm K. Brenner, Adrian P. Gee, Michele H. Cottler-Fox, Bart Barlogie, Cliona M. Rooney, Frits van Rhee
Journal: Blood (2012)
Functional characterization of IGFBP5 in the inhibition of osteosarcoma tumorgenicity.
Authors: G. Luther, E. Wagner, H. Luu, R. Haydon, T. C. He
Journal: Journal of Clinical Oncology (2011)

10038 Background: Osteosarcoma (OS) is the most common primary malignancy of bone. At presentation, the majority of patients have metastatic disease. Therefore, there is a clinical need to identify molecular markers that provide insight into the pathogenesis OS. The goal of this investigation is to functionally characterize the novel marker, IGFBP5, in osteosarcoma tumor progression. Methods: We created adenoviral constructs expressing the unique domains of IGFBP5 (N-term, C-term, linker), full length IGFBP5, and siIGFBP5. We conducted in vitro and in vivo assays on adenovirally infected OS cell lines MG63, MG63.2, and 143B. Western blot and immunohistochemical (IHC) staining were used to assay the apoptotic marker Caspase 3. Cell migration and invasion were measured using Wound Healing and Matrigel assays. Osteoblastic differentiation was measured using alkaline phosphastase activity and IHC staining for the late osteogenic markers osteocalcin and osteopontin. Finally, clinical patient samples were stained for IGFBP5 expression in patient matched primary tumors and metastatic pulmonary lesions. Results: IGFBP5 inhibited in vitro cell proliferation, migration and invasion of OS cells. Additionally, IGFBP5 overexpression promoted apoptosis and osteogenic differentiation. Analysis of the three functional domains indicated that the N-terminal domain was primarily responsible for inhibiting cell proliferation and inducing apoptosis, while the C-terminal domain inhibited cell migration and invasiveness. In an orthotopic animal model, overexpression of IGFBP5 inhibited OS tumor growth and lung metastasis, while siRNA-mediated knockdown of IGFBP5 promoted OS tumor growth and lung metastasis. IHC staining of clinical OS samples confirmed that primary OS tumors expressed significantly lower levels of IGFBP5 than their corresponding pulmonary metastases. Conclusions: These results suggest that IGFBP5 is a novel marker in OS pathogenesis, and the loss of IGFBP5 function may contribute to more metastatic phenotypes in OS. Furthermore, while the N-terminal domain of IGFB5 is responsible for inhibition of cell proliferation, the C-terminal domain is responsible for inhibiting cell invasion and migration.
Safety and Efficacy of Directly Acting Antivirals in 2432 HCV Patients with Advanced Fibrosis: An Interim Analysis of the Lombardia Regional Network for Viral Hepatitis
Authors: A.M. Aghemo, G. Cologni, F. Maggiolo, L. Pasulo, G. Rizzardini, C. Magni, T. Quirino, L. Minoli, G. Filice, M. Zuin, A. Colli, M. Rumi, M. Puoti, S. Fagiuoli, M. Colombo
Journal: Journal of Hepatology (2016)
Cost-Effectiveness of Elbasvir (EBR, MK-8742)/Grazoprevir (GZR, MK-5172) Use in Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Virus (HCV) Genotype 1 Infection and Chronic Kidney Disease (CKD) in the United States
Authors: E. Elbasha, W. Greaves, C. Nwankwo
Journal: Journal of Hepatology (2016)
Liver Fibrosis Evaluation Using Real-Time Shear Wave Elastography: Applicability, Association with Activity and Steatosis, and Diagnostic Performance. Direct Comparisons with Transient Rlastography Using Biomarkers as References
Authors: T. Poynard, T. Pham, H. Perazzo, E. Luckina, M. Munteanu, D. Elaribi, Y. Ngo, L. Bonyhay, N. Seurat, M. Legroux, A. Ngo, O. Deckmyn, D. Thabut, V. Ratziu, O. Lucidarme
Journal: Journal of Hepatology (2016)
A Multicentre, Phase II, Open-Label, Randomised Controlled Trial of Repeated Autologous Infusions of Granulocyte Colony Stimulating Factor Mobilised Cd133 + Bone Marrow Stem Cells in Patients with Cirrhosis
Authors: P.N. Newsome, R. Fox, A. King, N. Than, J. Moore, C. Corbett, S. Townsend, D. Barton, H. Beard, A. Atkinson, C. Bienek, N. McGowan, J. Campbell, J. Keeley, J. Thomas, K. Guo, D. Hull, I. Guha, D. Hollyman, D. Stocken, C. Yap, S. Forbes
Journal: Journal of Hepatology (2016)
High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis with Ombitasvir/Paritaprevir/Ritonavir Co-Administered with Ribavirin (AGATE-I)
Authors: T. Asselah, C. Hezode, R.B. Qaqish, M. ElKhashab, T. Hassanein, G. Papatheodoridis, J. Feld, S. Alqahtani, T. Pilot-Matias, Y. Yu, R. Redman, N. Mobashery
Journal: Journal of Hepatology (2016)
Sofosbuvir/Ledipasvir in Spanish Prison Population with Chronic Hepatitis C
Authors: F. Fernandez-Gonzalez, A.M. Matilla-Peña, P. Gijón-Vidaurreta, E. Acín-García, D. Rincón-Rodríguez, E. Reigadas-Ramírez, G.C. Ricote
Journal: Journal of Hepatology (2016)
Infographic. Physical activity for early years
Authors: Hamish Reid, Sally Davies, Catherine Calderwood, Frank Atherton, Michael McBride, Charlie Foster
Journal: British Journal of Sports Medicine (2016)

The 2011 UK Chief Medical Officers' (CMOs') Physical Activity (PA) guidelines were the first to include recommendations for the early years. They reflect the body of evidence on the importance of PA before the age of five.1 Regular PA underpins physical, cognitive and social development; whilst early childhood inactivity brings a very high risk of poor health …
A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results
Authors: C. L. Vogel, H. A. Burris, S. Limentani, R. Borson, J. O'Shaughnessy, S. Vukelja, S. Agresta, B. Klencke, M. Birkner, H. Rugo
Journal: Journal of Clinical Oncology (2009)

1017 Background: T-DM1 is an ADC that combines the biological activity of trastuzumab (T) with targeted delivery of a potent antimicrotubule agent, DM1, to HER2-expressing cancer cells. In a phase I study, T-DM1 was administered IV q3w to pts with HER2+ MBC who had progressed on T + chemotherapy. T-DM1 was well-tolerated at the maximum tolerated dose (MTD) of 3.6 mg/kg, with no reports of cardiac toxicity. The confirmed objective response rate (ORR) for the 9 pts with measurable disease treated at the MTD was 44%. The phase II study described here further assesses tolerability and activity of T-DM1. Methods: This was a multi-institutional, open-label, single-arm phase II study, to enroll 100 pts. All eligible pts had progressed on HER2-directed therapy and had received chemotherapy in the metastatic setting. T-DM1 was administered at 3.6 mg/kg IV q3w. Primary objectives were assessment of ORR and of safety and tolerability. Results: As of the August 29, 2008, data-cut, 112 patients had enrolled, with baseline median age 54.5 (range 33–82); ECOG PS 2 or 3, 80%; 68.7% with &gt; 3 sites of metastatic disease; median 3 (range 1–14) prior chemotherapy agents for metastatic disease, median 76.3 weeks prior T, and 55.4% with previous lapatinib. Due to limited F/U, the median number of T-DM1 cycles received was 5 (range 1–16), and 19 of the 107 efficacy evaluable patients had only one post-baseline tumor assessment. Fifty-six pts had discontinued study treatment. With a median follow-up of 4.4 mos, there were 42 (39.3%) ORs (CR or PR), 29 (27.1%) of which have been confirmed by follow-up (F/U) imaging. Among the subgroup of pts who had either &gt;6 months F/U or had discontinued from the study at any time (n = 76) there were 33 ORs (43.4%), 29 (38.2%) of which were confirmed by F/U imaging. The most common grade 3–4 AE was thrombocytopenia (7.1%). Updated data will be presented at the meeting, including updated ORR, 6-month clinical benefit rate, ORR by independent review, progression-free survival, and duration of response. Conclusions: T-DM1 has single-agent activity in pts with previously treated, HER2+ MBC, and is well tolerated at the recommended phase II dose. [Table: see text]